Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has shared an announcement.
Shanghai Henlius Biotech, Inc. has announced a series of organizational changes, including the re-designation of Mr. Wenjie Zhang from an executive to a non-executive director, effective March 24, 2025. Additionally, Dr. Jun Zhu has been appointed as an authorized representative, and the company is proposing amendments to its Articles of Association to align with updated laws and regulations, subject to shareholder approval at the upcoming annual general meeting.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development and commercialization of monoclonal antibody drugs. The company is engaged in providing innovative treatment solutions, primarily targeting oncology and autoimmune diseases.
YTD Price Performance: 28.69%
Average Trading Volume: 1,441,157
Technical Sentiment Signal: Sell
Current Market Cap: HK$16.58B
See more insights into 2696 stock on TipRanks’ Stock Analysis page.